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neurogenesis and neuroplasticity of the brain. This systematic review was designed 
to	 examine	 the	 association	between	BDNF	Val66Met	 (rs6265)	 polymorphism	and	
four	cognitive	domains—attention	and	concentration,	executive	function,	verbal	flu-
ency,	and	memory,	respectively.
Methodology: Primary literature search was performed using search engines such as 
PubMed	and	Scopus.	Observational	studies	that	evaluated	the	neurocognitive	per-
formances	in	relation	to	BDNF	polymorphism	within	human	subjects	were	included	
in	 this	 review,	 while	 animal	 studies,	 overlapping	 studies,	 and	 meta-	analysis	 were	
excluded.
Results:	 Forty	 of	 82	 reviewed	 studies	 (48.8%)	 reported	 an	 association	 between	
Val66Met	polymorphism	and	neurocognitive	domains.	The	proportion	of	the	studies	
showing	positive	findings	in	cognitive	performances	between	Val/Val	homozygotes	
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1  | INTRODUC TION
The	brain-	derived	neurotrophic	factor	(BDNF)	belongs	to	the	neu-
rotrophin superfamily and has an essential role in the neurogenesis 
and	neuroplasticity	of	the	brain	(Matsuo	et	al.,	2009).	The	signaling	
BDNF	 supports	 the	 survival	 of	 existing	 neurons	 and	 encourages	
the proliferation and differentiation of new neurons and synapses 
in	both	the	central	and	peripheral	nervous	system	 (Acheson	et	al.,	
1995;	Huang	&	Reichardt,	 2001).	 In	 the	brain,	BDNF	 is	 highly	 ex-
pressed	 in	 the	 hippocampus,	 cortex,	 and	 basal	 forebrain	 and	 has	
an important role in regions that are vital to learning and memory 
(Bekinschtein,	Cammarota,	&	Katche,	2008).
The	expression	of	BDNF	is	encoded	by	the	BDNF	gene	which	has	




















polymorphism with cognitive performance in various disease states. 





ulate	 learning	 and	memory,	 it	would	 be	 of	 interest	 to	 understand	
how	 the	 BDNF	 rs6265	 polymorphism	 influence	 specific	 cognitive	








and	 Scopus	 in	 July	 2015.	 The	 search	 included	 articles	 published	
exclusively	 in	English	dated	up	to	1	May	2017.	No	screening	limits	




Bibliographies of relevant articles were also reviewed.
2.2 | Inclusion/exclusion criteria
Published studies were included into the systematic review if they 
fulfilled	the	following	inclusion	criteria:	(a)	evaluated	cognitive	per-
formance	 in	 relation	 to	 the	BDNF	 rs6265	 polymorphism	 in	 either	







(IQ)	 have	 been	 used	 to	 evaluate	 cognitive	 performance	 in	 the	
human	 population.	 This	 is	 because	 MMSE	 not	 only	 lacks	 sensi-
tivity	 in	 identifying	mild	cognitive	 impairment,	but	 the	scores	are	
also	 influenced	 by	 demographic	 factors	 such	 as	 age,	 education,	
cultural,	 and	 socioeconomic	background.	Conversely,	 studies	uti-
lizing	IQ	test	as	an	outcome	were	excluded	because	IQ	test	is	not	





Three	 investigators	 independently	extracted	 the	data	using	a	pre-
designed,	piloted	form.	Each	study	was	reviewed,	and	the	relevant	
information	 was	 extracted	 and	 compiled.	 The	 following	 informa-
tion	was	extracted	from	each	study:	study	objectives,	study	design,	






The attention and concentration domain determine the content 
of	consciousness	and	influence	the	quality	of	conscious	experience,	
while	 the	executive	 function	domain	 represents	 the	ability	 to	 rea-
son,	 plan,	 and	execute.	Verbal	 fluency	domain	 is	 related	 to	 verbal	
functioning,	 which	 involves	 the	 semantic	 and	 phonemic	 fluency.	
Memory	 encompasses	 a	 broad	 domain	which	 includes	 declarative	
memory	tasks	for	verbal	tasks,	associative	memory	as	well	as	work-
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3  | RESULTS




ating each cognitive domain was identified; attention and concentra-
tion	(n	=	23),	executive	function	(n	=	47),	verbal	fluency	(n	=	18),	and	
memory	(n	=	63).	The	included	studies	examined	genetic	association	
with neurocognition in healthy patients and other disease states. 
In	 total,	 40	 of	 the	 82	 reviewed	 studies	 (48.8%)	 (Aas	 et	al.,	 2013;	
Alfimova,	Korovaitseva,	Lezheiko,	&	Golimbet,	2012;	Altmann	et	al.,	
2016;	Avgan	et	al.,	 2017;	Barbey	et	al.,	 2014;	Canivet	 et	al.,	 2015;	
Cao	et	al.,	2016;	De	Beaumont,	Fiocco,	Quesnel,	Lupien,	&	Poirier,	
2013;	 Egan,	 Kojima,	 &	 Callicott,	 2003;	 Freundlieb	 et	al.,	 2015;	
Gajewski,	Hengstler,	Golka,	Falkenstein,	&	Beste,	2011;	Gong	et	al.,	
2009;	Gonzalez	et	al.,	2016;	Gonzalez-	Giraldo	et	al.,	2014;	Gosselin	
et	al.,	 2016;	 Ho,	 Andreasen,	 Dawson,	 &	 Wassink,	 2007;	 Huang	
et	al.,	2014;	Jasinska	et	al.,	2016;	Kim	et	al.,	2016;	Lamb,	Thompson,	
McKay,	Waldie,	 &	 Kirk,	 2015;	 Lee,	 Baek,	 &	 Kim,	 2015;	 Lim	 et	al.,	
2013,	2016;	Miyajima	et	al.,	2008;	McAllister	et	al.,	2012;	Nagata,	
Shinagawa,	 Nukariya,	 Yamada,	 &	 Nakayama,	 2012;	 Narayanan	
et	al.,	2016;	Ng	et	al.,	2016;	Raz,	Rodrigue,	Kennedy,	&	Land,	2009;	
Richter-	Schmidinger	 et	al.,	 2011;	 Rybakowski,	 Borkoswka,	Czerski,	
Skibinska,	&	Hauser,	2003;	Rybakowski	et	al.,	2006;	Schofield	et	al.,	






A	 total	 of	 23	 studies	 evaluated	 the	 association	 between	 the	
BDNF	 polymorphism	 and	 the	 attention/concentration	 domain	
(Alfimova	 et	al.,	 2012;	 Cherubin	 et	al.,	 2014;	 da	 Rocha,	 Malloy-	
Diniz,	Lage,	&	Correa,	2011;	Dennis	et	al.,	2011;	Freundlieb	et	al.,	
2012;	 Freundlieb	 et	al.,	 2015;	 Gatt	 et	al.,	 2007;	Ho	 et	al.,	 2006;	








Schofield	et	al.,	2009;	Ward	et	al.,	2015),	 and	 the	 rest	evaluated	
samples	 of	 different	 disease	 states	 such	 as	 Alzheimer’s	 disease	
(n	=	1)	(Lin	et	al.,	2016),	cardiovascular	diseases	(n	=	2)	(Swardfager	
et	al.,	 2011;	 Szabo	 et	al.,	 2013),	 obsessive-	compulsive	 disorder	
(n	=	2)	 (da	 Rocha	 et	al.,	 2011;	 Tukel	 et	al.,	 2012),	 schizophrenia	
(n	=	5)	 (Ho	 et	al.,	 2006;	 Kim	 et	al.,	 2016;	Mezquida	 et	al.,	 2016;	
Zhang	et	al.,	2012,	2016),	traumatic	brain	injury	(n	=	2)	(Narayanan	
et	al.,	 2016;	 Yu	 et	al.,	 2008),	 and	 systemic	 lupus	 erythematous	
(n	=	1)	(Oroszi	et	al.,	2006).
Among	 the	 reviewed	 studies,	 four	 studies	 (17.4%)	 (Kim	 et	al.,	
2016;	Narayanan	et	al.,	2016;	Szabo	et	al.,	2013;	Zhang	et	al.,	2012)	
observed	significant	positive	association	between	BDNF	Val66Met	





Search strategy: “BDNF” AND “Val66Met” AND “polymorphism” or 
“BDNF” AND “Val66Met” AND “neurocognition”
2 databases searched: 
PubMed (n = 889), Scopus (n= 776)
Abstracts reviewed for 
relevance to Val66Met 
polymorphism on 
neurocognition
N = 1359 excluded
N = 306
Number of articles screened for Eligibility: PubMed (n = 210), Scopus (n = 96)
Manual review of reference lists of identified studies = 0 nonredundant studies identified
N = 82
Studies after initially excluding studies
N = 224 excluded
n = 8 animal studies
n = 20 reviews
n = 195 article overlapping
n= 1 case-control study
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concentration	over	 time	 (Narayanan	et	al.,	 2016).	Conversely,	Met	
carriers	were	reported	to	perform	better	than	Val/Val	homozygotes	
in attention/concentration domain in another study focusing on el-
derly	 population	with	 cardiovascular	 diseases	 (Szabo	 et	al.,	 2013).	
In	studies	conducted	in	the	schizophrenic	population,	one	reported	
that	 Val/Val	 homozygotes	 had	 better	 attention	 performance	 than	
carriers	of	Met/Met	homozygotes	(Zhang	et	al.,	2012),	while	another	
study	reported	the	association	of	Val	allele	with	poorer	neurocog-
nitive	 function	 in	 the	 attention/concentration	 domain	 (Kim	 et	al.,	
2016).
3.2 | Executive function domain
Forty-	seven	 relevant	 studies	were	 identified	within	 the	 executive	
function domain. Twenty studies evaluated on healthy subjects 
(Alfimova	et	al.,	2012;	Cherubin	et	al.,	2014;	Dennis	et	al.,	2011;	De	
Beaumont	et	al.,	2013;	Erickson	et	al.,	2013;	Freundlieb	et	al.,	2012;	
Freundlieb	 et	al.,	 2015;	 Gong	 et	al.,	 2009;	 Gajewski	 et	al.,	 2011;	
Ghisletta	 et	al.,	 2014;	 Gonzalez	 et	al.,	 2016;	 Harris	 et	al.,	 2006;	
Huang	et	al.,	2014;	Lim	et	al.,	2013;	Schofield	et	al.,	2009;	Thibeau,	
McFall,	Wiebe,	Anstey,	&	Dixon,	2016;	Thow	et	al.,	2017;	Ward	et	al.,	
2014,	 2015;	Wilkosc	 et	al.,	 2016),	 and	 the	 rest	 evaluated	 samples	
of	different	disease	 states	 such	as	Alzheimer’s	disease	 (n	=	4)	 (Lee	
et	al.,	2015;	Lin	et	al.,	2016;	Nagata	et	al.,	2011,	2012),	Parkinson’s	






traumatic	brain	 injury	 (n	=	4)	 (Barbey	et	al.,	2014;	McAllister	et	al.,	
2012;	Narayanan	et	al.,	2016;	Yu	et	al.,	2008),	depression	(n	=	1)	(Yin	
et	al.,	2015),	multiple	sclerosis	(n	=	1)	(Fera	et	al.,	2013),	breast	can-
cer	patients	 (n	=	1)	 (Ng	et	al.,	2016),	systemic	 lupus	erythematosus	
(n	=	1)	(Oroszi	et	al.,	2006),	and	psychosis	(n	=	1)	(Aas	et	al.,	2013).
Out	of	the	47	studies,	18	studies	(38.3%)	(Alfimova	et	al.,	2012;	
Altmann	 et	al.,	 2016;	 Barbey	 et	al.,	 2014;	 Freundlieb	 et	al.,	 2015;	




reported	 significant	 association	 between	 BDNF	 Val66Met	 poly-
morphism	and	 the	executive	 function	domain.	Among	 these	 stud-
ies,	 11	 studies	 (23.4%)	 (Alfimova	 et	al.,	 2012;	 Barbey	 et	al.,	 2014;	
Freundlieb	et	al.,	2015;	Gonzalez	et	al.,	2016;	Kim	et	al.,	2016;	van	
der	 Kolk	 et	al.,	 2015;	 McAllister	 et	al.,	 2012;	 Nagata	 et	al.,	 2012;	
Ng	 et	al.,	 2016;	 Szabo	 et	al.,	 2013;	 Yin	 et	al.,	 2015)	 reported	 that	
Met	 carriers	 performed	 significantly	 better	 than	Val/Val	 homozy-
gotes	in	healthy	controls	and	populations	with	Alzheimer’s	disease,	
Parkinson’s	 disease,	 cardiovascular	 diseases,	 traumatic	 brain	 in-
jury,	 and	depression.	One	 study	 reported	 that	 genotypes	of	Met/











polymorphism within the verbal fluency domain. These studies eval-
uated populations of different disease states such as healthy controls 
(n	=	11)	 (Alfimova	et	al.,	2012;	De	Beaumont	et	al.,	2013;	Gajewski	
et	al.,	2011;	Gong	et	al.,	2009;	Freundlieb	et	al.,	2012,	2015;	Harris	
et	al.,	 2006;	 Huang	 et	al.,	 2014;	 Karnik,	 Wang,	 Barch,	 Morris,	 &	
Csernansky,	 2010;	 Schofield	 et	al.,	 2009;	Ward	 et	al.,	 2015),	 trau-
matic	brain	injury	(n	=	1)	(Yu	et	al.,	2008),	obsessive-	compulsive	dis-
order	 (n	=	1)	 (Tukel	et	al.,	2012),	psychosis	 (n	=	2)	 (Aas	et	al.,	2013;	
Martinho	et	al.,	2012),	Parkinson’s	disease	(n	=	1)	(van	der	Kolk	et	al.,	
2015),	cardiovascular	diseases	(n	=	1)	(Szabo	et	al.,	2013),	and	breast	




Sixty-	three	 studies	 were	 identified	 under	 the	 memory	 domain.	




2010;	 Canivet	 et	al.,	 2015;	 Chen	 et	al.,	 2015,	 2016;	 Dennis	 et	al.,	
2011;	De	Beaumont	 et	al.,	 2013;	 Erickson	 et	al.,	 2013;	 Freundlieb	
et	al.,	 2015;	 Gajewski	 et	al.,	 2011;	 Gong	 et	al.,	 2009;	 Gonzalez-	
Giraldo	 et	al.,	 2014;	 Gosselin	 et	al.,	 2016;	 Huang	 et	al.,	 2014;	
Jasinska	et	al.,	2016;	Karnik	et	al.,	2010;	Kennedy	et	al.,	2015;	Lim	
et	al.,	2013;	Liu	et	al.,	2014;	Lamb	et	al.,	2015;	Miyajima	et	al.,	2008;	
Montag	 et	al.,	 2014;	 Raz	 et	al.,	 2009;	 Richter-	Schmidinger	 et	al.,	
2011;	Schofield	et	al.,	2009;	Stuart,	Summers,	Valenzuela,	&	Vickers,	
2014;	Thow	et	al.,	 2017;	Voineskos	et	al.,	 2011;	Ward	et	al.,	 2014,	
2015;	Wilkosc	et	al.,	2016;	Wegman,	Tyborowska,	Hoogman,	Arias	
Vásquez,	 &	 Janzen,	 2016;	 Yogeetha	 et	al.,	 2013),	 dementia	 (n	=	1)	
(Kim	 et	al.,	 2015),	 Alzheimer’s	 (n	=	3)	 (Gomar,	 Conejero-	Goldberg,	
Huey,	Davies,	&	Goldberg,	2016;	Lim	et	al.,	2016;	Lin	et	al.,	2016),	
Parkinson’s	 (n	=	1)	 (Bialecka	 et	al.,	 2014),	 cardiovascular	 disease	
(n	=	2)	 (Swardfager	 et	al.,	 2011;	 Szabo	 et	al.,	 2013),	 obsessive-	
compulsive	 disease	 (n	=	1)	 (Tukel	 et	al.,	 2012),	 multiple	 sclerosis	
(n	=	1)	(Fera	et	al.,	2013),	psychosis	(n	=	2)	(Aas	et	al.,	2013;	Martinho	
et	al.,	 2012),	 depression/anxiety	 disorders	 (n	=	2)	 (Molendijk	 et	al.,	
2012;	Strauss,	Barr,	&	George,	2004),	brain	injury	(n	=	2)	(McAllister	
et	al.,	2012;	Narayanan	et	al.,	2016),	amnestic	mild	cognitive	impair-
ment	 (n	=	1)	 (Yu	 et	al.,	 2008),	 schizophrenia	 and	 bipolar	 disorders	
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(n	=	9)	 (Cao	 et	al.,	 2016;	 Egan	 et	al.,	 2003;	 Ho	 et	al.,	 2006,	 2007;	
Kim	et	al.,	2016;	Mezquida	et	al.,	2016;	Rybakowski	et	al.,	2003;	Tan	










2011;	 Schofield	 et	al.,	 2009;	 Szabo	 et	al.,	 2013;	 Tukel	 et	al.,	 2012;	
Tan	et	al.,	2005;	Yogeetha	et	al.,	2013)	observed	significant	positive	
association	 between	BDNF	Val66Met	 polymorphism	 and	memory	
domain.
Nineteen	of	these	identified	studies	(30.2%)	(Aas	et	al.,	2013;	
Canivet	et	al.,	 2015;	Cao	et	al.,	 2016;	De	Beaumont	et	al.,	 2013;	
Egan	et	al.,	2003;	Gong	et	al.,	2009;	Gosselin	et	al.,	2016;	Ho	et	al.,	
2006;	 Jasinska	 et	al.,	 2016;	 Lamb	 et	al.,	 2015;	 Lim	 et	al.,	 2016;	
Miyajima	et	al.,	2008;	Narayanan	et	al.,	2016;	Richter-	Schmidinger	
et	al.,	 2011;	 Raz	 et	al.,	 2009;	 Schofield	 et	al.,	 2009;	 Tan	 et	al.,	




tively.	 Conversely,	 Met	 carriers	 were	 found	 to	 perform	 better	
in	 memory	 tasks	 in	 seven	 of	 such	 studies	 (11.1%)	 that	 evaluate	








ies indicated a presence of association with cognitive domains in 













morphism has an influence on neurocognition.
Among	 the	 various	 cognitive	 domains	 evaluated,	 the	 domain	
of memory has the strongest evidence to suggest the role of the 
Val66Met	 polymorphism	 in	 neurocognition.	Overall,	 19	 of	 the	 re-
viewed	studies	reported	Val/Val	homozygotes	performing	better	in	
memory-	related	tasks	compared	to	Met	carriers	who	were	favored	




terms of memory are aligned with the results from a meta- analysis 
previously	conducted	 (Kambeitz	et	al.,	2012).	 In	the	meta-	analysis,	
results	suggested	that	BDNF	Val66Met	polymorphism	accounts	for	




morphism as there were different forms of memory that were re-
viewed.	The	hippocampus	region	where	BDNF	is	highly	expressed	at	
is mainly responsible for consolidating short- term memory into long- 
term	memory	and	the	spatial	memory	(Bekinschtein	et	al.,	2008).	In	
fact,	the	distinct	phenotypes	of	memory	that	were	reviewed	include	
but	 are	 not	 limited	 to	 episodic	 memory,	 associative	memory,	 and	
working memory.
The	 various	 types	 of	 memory	 would	 require	 an	 independent	
measure	of	their	own	and	are	likely	to	be	influenced	by	BDNF	poly-
morphism	to	varying	extents.	In	order	to	make	reliable	and	reason-




compared	 to	 the	other	genotypes,	 they	 scored	worse	on	measure	
of	visual	memory	(Yogeetha	et	al.,	2013).	In	another	study	looking	at	
schizophrenia	population,	genotypes	of	Val/Val	homozygotes	were	
found to have better verbal memory and logical episodic memory 
(Zhang	et	al.,	2012).	While	it	appears	that	Val66Met	polymorphism	
confers	 better	 verbal	memory,	 it	 is	 noteworthy	 that	 our	 reviewed	
studies	 did	 not	 show	 an	 association	with	 verbal	 fluency	 (Table	1).	
This indicates that there may be some specificity of association of 
Val66Met	polymorphisms	with	the	respective	cognitive	domains.
Another	objective	measure	worth	exploring	as	a	basis	of	com-
parison across studies is to conduct neuroimaging analysis such as 
fMRI	 to	 assess	 actual	 neural	 activation	 in	 brain	 activity.	 A	 meta-	
analysis	conducted	found	no	significant	association	between	BDNF	
Val66Met	polymorphism	and	hippocampal	 volumes	 in	healthy	hu-
mans,	with	 hippocampal	 volumes	 being	 of	 interest	 because	 it	 is	 a	
well- established brain region that has an important role in learning 
and	memory.	However,	the	findings	observed	that	Met	carriers	had	
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regions that are activated when correlating with cognitive function. 
This would enhance our mechanistic understanding behind the bio-
logical mechanism.
With	regards	to	the	attention/concentration	domain,	 it	was	 in-
teresting to note that positive associations were identified only in 
cohorts with specific disease states. The findings from one study 
favors	Met	 carriers,	 suggesting	 that	Met	 allele	 favorably	 interacts	
with cognitive changes associated with the cardiovascular dis-
ease or that cardiovascular diseases may have affected circulating 
levels	of	BDNF,	given	 that	BDNF	 is	permeable	 to	 the	blood–brain	
barrier	 (Szabo	et	al.,	 2013).	Another	 study	 finds	 that	Met	 carriers,	
regardless	of	whether	they	were	healthy	controls	or	schizophrenic,	
performed	 worse	 than	 genotypes	 of	 Val/Val	 homozygotes	 in	 the	
attention/concentration	 domains	 (Zhang	 et	al.,	 2012).	 It	 is	 pos-
tulated	 that	 hippocampal	 neurons	 that	 contain	Met	 allele	 showed	
less	 depolarization-	induced	 BDNF	 secretion,	 resulting	 in	 reduced	





in	 human	 lesion	 patients	 on	 Val66Met	 polymorphism	 has	 shown	
that	Met	allele	exerts	a	protective	effect	for	executive	function	 in	





morphism.	Consequentially,	 cognitive	 reserve	was	 reported	 to	 ac-
count	for	up	to	8.5%	of	the	variance	in	executive	function	in	Val/Val	
homozygotes	(Ward	et	al.,	2015).
There are suggestions that certain disease states could be pref-
erentially	 influenced	by	the	 impact	of	the	Met	allele	on	neurocog-











Attention and concentration 
(%) Executive function (%) Verbal fluency Memory (%)
Total studies 23 47 18 63
Presence of association 4	(17.4) 18	(38.3) 0 26	(41.3)
Extent	of	association
Favoring	Val/Val	homozygotes 2	(8.70) 7	(14.9) 0 19	(30.2)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
2	(8.70) 11	(23.4) 0 7	(11.1)
(b)
Domains of interest (n = total)
Attention and concentration 
(n = 23)
Executive function 
(n = 47) (%) Verbal fluency (n = 18)
Memory 
(n = 63) (%)
Number	of	studies 10 20 11 36
Presence of association 0 4	(8.51) 0 16	(25.4)
Extent	of	association
Favoring	Val/Val	homozygotes 0 1	(2.12) 0 11	(17.5)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
0 3	(6.40) 0 5	(7.94)
(c)
Domains of interest (n=total)
Attention and concentration 
(n = 23) (%)
Executive function 
(n = 47) (%) Verbal fluency (n = 18)
Memory 
(n = 63) (%)
Number	of	studies 13 27 7 27
Presence of association 4	(17.4) 14	(29.8) 0 10	(15.9)
Extent	of	association
Favoring	Val/Val	homozygotes 2	(8.70) 6	(12.8) 0 8	(12.7)
Favoring	Met	carriers	(Val/Met	and	
Met/Met)
2	(8.70) 8	(17.0) 0 2	(3.17)
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TABLE  2 List	of	reviewed	studies	showing	the	direction	of	association	between	Val66Met	polymorphism	and	the	respective	
neurocognitive	domains	for	healthy	individuals	(N	=	42)





effectVal/Val (%) Met carriers (%)
Thow	et	al.	(2017) Healthy	adults 322	(72.6) 121	(27.4) M,	EF − NA
Bombardier	et	al.	(2016) Healthy	adults 49	(65.3) 26	(34.7) M − NA
Wegman	et	al.	(2016) Healthy	adults 18	(48.6) 19	(51.4) M − NA
Wilkosc	et	al.	(2016) Healthy	adults N	=	460 M,	EF − NA
Thibeau	et	al.	(2016) Healthy	adults 380	(65.9) 197	(34.1) EF − NA
Chen	et	al.	(2016) Healthy	adults 113	(27.0) 304	(73.0) M − NA
Chen	et	al.	(2015) Healthy	adults 25	(22.8) 85	(77.2) M − NA
Ward	et	al.	(2015) Healthy	adults 286	(66.1) 147	(33.9) A,	EF,	VF,	M − NA
Cherubin	et	al.	(2014) Healthy	adults 261	(65.3) 139	(34.7) A,	EF − NA
Ward	et	al.	(2014) Healthy	adults 282	(66.8) 140	(33.2) M,	EF − NA
Ghisletta	et	al.	(2014) Healthy	adults 239	(66.0) 123	(34.0) EF − NA
Montag	et	al.	(2014) Healthy	adults 93	(67.0) 45	(33.0) M − NA
Stuart	et	al.	(2014) Healthy	adults 236	(65.6) 124	(34.4) M − NA
Kennedy	et	al.	(2015) Healthy	adults 79	(68.1) 37	(31.9) M − NA
Liu	et	al.	(2014) Healthy	adults 86	(26.1) 244	(73.9) M − NA
Erickson	et	al.	(2013) Healthy	adults 671	(65.0) 361	(35.0) M,	EF − NA
Freundlieb	et	al.	(2012) Healthy	adults 22	(57.9) 16	(42.1) A,	EF,	VF − NA
Dennis	et	al.	(2011) Healthy	adults 11	(50.0) 11	(50.0) A,	EF,	M − NA
Voineskos	et	al.	(2011) Healthy	adults 41	(59.5) 28	(40.5) M − NA
Beste	et	al.	(2011) Healthy	adults 119	(56.4) 92	(43.6) M − NA
Karnik	et	al.	(2010) Healthy	adults 87	(67.4) 42	(32.6) M,	VF − NA
Cathomas	et	al.	(2010) Healthy	adults 203	(61.0) 130	(39.0) M − NA
Gatt	et	al.	(2007) Healthy	adults 242	(64.7) 132	(35.3) A − NA
Harris	et	al.	(2006) Healthy	adults 589	(65.2) 315	(34.8) EF,	VF − NA
Huang	et	al.	(2014) Healthy	adults 20	(22.2) 70	(77.8) A,	EF,	VF,	M + Met	carriers	
(M)
Avgan	et	al.	(2017) Healthy	adults N = 181 M + Met	carriers	
(M)
Jasinska	et	al.	(2016) Children 55	(67.9) 26	(32.1) M + Val/Val	(M)
Gosselin	et	al.	(2016) Healthy	adults 79	(73.8) 28	(26.2) M + Val/Val	(M)
Canivet	et	al.	(2015) Elderly 118	(57.5) 87	(42.5) M + Val/Val	(M)
Lamb	et	al.	(2015) Healthy	adults 53	(53.0) 47	(47.0) M + Val/Val	(M)
Gonzalez	et	al.	(2016) Healthy	adults N	=	167 EF + Met	carriers	
(EF)




Healthy	adults 129	(77.0) 39	(23.0) M + Met	carriers	
(M)
Lim	et	al.	(2013) Healthy	adults 107	(64.8) 58	(35.2) EF,	M,	A + Val/Val	(EF)
Yogeetha	et	al.	(2013) Healthy	adults 113	(62.4) 68	(37.6) M + Val/Val	(M)
De	Beaumont	et	al.	(2013) Healthy	adults 80	(60.6) 52	(39.4) M,	EF,	VF + Val/Val	(M)
Alfimova	et	al.	(2012) Healthy	adults 257	(64.0) 144	(36.0) A,	EF,	VF,	M + Met	carriers	
(EF)	(M)
(Continues)
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In	some	instances,	poorer	neurocognition	could	be	attributed	
to	neurodegenerative	diseases	 itself	 rather	than	BDNF	polymor-
phism,	 confounding	 the	 actual	 extent	 of	 effect	 from	 the	 BDNF	
genotype. Disease states which affect cognitive function may 
mask or worsen the effect of genetic polymorphism on cognition. 
While	BDNF	polymorphism	was	not	significantly	associated	with	
serum	BDNF,	this	polymorphism	is	believed	to	influence	intracel-
lular	 sorting	 of	 BDNF,	 resulting	 in	 decreased	 synaptic	 plasticity	
(Bath	 &	 Lee,	 2006;	 Binder	 &	 Scharfman,	 2004).	 The	 biological	
function	of	pro-	BDNF	is	also	not	limited	in	being	an	inactive	pre-
cursor with some suggesting that it may have an antagonistic ef-
fect	 (Bath	&	Lee,	2006;	Binder	&	Scharfman,	2004).	The	overall	
physiological functions may be better correlated by a balance of 
both	pro	and	mature	BDNF,	so	measuring	BDNF	as	a	ratio	of	pro:	
mature	forms	might	be	a	more	accurate	reflection	of	BDNF	effect	
in relation to brain disorders. There are also variations attributed 
to	the	source	of	BDNF	as	levels	differ	from	plasma	to	serum	sam-
ples.	Our	 study	 posits	 that,	without	 the	 direct	 quantification	 of	
circulating	BDNF,	it	might	be	difficult	to	evaluate	the	association	
between	BDNF	genotype	and	cognitive	function.
In	 a	 study	 involving	 patients	 with	 Alzheimer’s	 disease,	 Met	
carriers	 were	 reported	 to	 have	 better	 executive	 function.	 It	 was	
suggested	 that	Met	 carriers	 are	 protected	 from	 the	 hippocampus	
cortical	atrophy	or	subcortical	tract	changes,	leading	to	them	having	
a	 decreased	 risk	 of	Alzheimer’s	 and	 improved	performance	 in	 do-
main	related	to	executive	function	(Nagata	et	al.,	2012).	However,	it	
remains unclear if the hippocampal atrophy is attributed to neuro-
psychiatric	disorders	or	the	extent	of	contribution	genetic	polymor-
phism has on its effect.
Conversely,	 in	 another	 study	 targeting	 at	 patients	 with	 high	
level	of	beta-	amyloid	(Aβ),	it	was	reported	that	there	is	greater	hip-
pocampal	 atrophy	 found	 in	Met	 carriers.	Met	 carriers	were	 found	




of	 Aβ	 on	memory	 found	 to	 be	 greater	 in	Met	 carriers	 (Lim	 et	al.,	





ily be related to its effect on brain region.
Old age could also be another factor that determines the direc-
tion	of	effect	BDNF	Val66Met	polymorphism	has	on	neurocognition	
as aging is often accompanied by decrease in hippocampus volume 
which	 is	associated	with	decline	 in	episodic	memory	 (Harrisberger	
et	al.,	 2014).	 Some	 studies	 have	 demonstrated	 that	 Met	 carriers	
are	more	protected	during	 aging	 than	Val/Val	 homozygotes	when	
it	comes	to	cognitive	function	such	as	executive	functions	that	 in-
volve	the	prefrontal	cortex.	For	some	aspects	of	memory,	Met	car-
riers	 were	 found	 to	 be	 performed	 poorly	 in	 associative	 memory,	
regardless	 of	 age.	BDNF	Val66Met	polymorphism	exerts	 an	 influ-
ence regardless of age on subjective and associative memory while 







phism on behavioral outcome of healthy young adults between 20 
and	30	years	old,	Met	carriers	tend	toward	better	performance.	It	is	
implied that the polymorphism can be an advantage or a disadvan-
tage	depending	on	the	tasks	examined	as	each	genotype	use	slightly	
different brain activation pattern as some performance- related 
tasks	may	be	more	dependent	on	BDNF	 (Dennis	et	al.,	2011).	 It	 is	
also	plausible	 that	BDNF	Val66Met	differences	on	neurocognition	
may be dependent on different developmental stages between ne-
onates,	children,	adolescents,	and	the	elderly.	To	address	this,	there	





effectVal/Val (%) Met carriers (%)
Gajewski	et	al.	(2011) Healthy	adults 79	(60.3) 52	(39.7) M,	EF,	VF + Met	carriers	
(M)
Richter- Schmidinger et al. 
(2011)
Healthy	adults 51	(37.8) 84	(62.2) M + Val/Val	(M)
Gong	et	al.	(2009) Healthy	adults 219	(30.8) 582	(69.2) M,	EF,	VF + Val/Val	(M)
Schofield	et	al.	(2009) Healthy	adults 282	(59.4) 193	(40.6) M,	A,	EF,	
VF
+ Val/Val	(M)
Raz	et	al.	(2009) Healthy	adults N = 189 M + Val/Val	(M)





     |  9 of 14TOH eT al.
TABLE  3 List	of	reviewed	studies	showing	the	direction	of	the	association	between	Val66Met	polymorphism	and	the	respective	
neurocognitive	domains	for	clinical	populations	(N	=	40)





effectVal/Val (%) Met carriers (%)
Wei	et	al.	(2017) On	GnRH	agonist 29	(74.3) 10	(25.7) M − NA
Lee	et	al.	(2016) Bipolar disorder 80	(22.5) 275	(77.5) EF − NA
Lin	et	al.	(2016) Alzheimer 55	(29.5) 131	(70.5) M,	EF,	A − NA
Gomar	et	al.	(2016) Alzheimer 153	(69.0) 69	(31.0) M − NA
Mezquida	et	al.	(2016) Schizophrenia 124	(62.6) 74	(37.4) M,	EF,	A − NA
Kim	et	al.	(2015) Dementia 300	(65.0) 160	(35.0) M − NA
Bialecka	et	al.	(2014) Parkinson 176	(72.1) 68	(27.9) M,	EF − NA
Fera	et	al.	(2013) Sclerosis 12	(46.2) 14	(53.8) M,	EF − NA
Martinho	et	al.	(2012) Psychosis 88	(67.7) 42	(32.3) M,	VF − NA
Molendijk	et	al.	(2012) Depression 82	(65.1) 44	(34.9) M − NA
da	Rocha	et	al.	(2011) OCD 82	(67.2) 40	(32.8) A,	EF − NA
Swardfager	et	al.	(2011) Cardiovascular 55	(65.5) 29	(34.5) A,	EF,	M − NA
Nagata	et	al.	(2011) Alzheimer 45	(26.6) 124	(73.4) EF − NA
Yu	et	al.	(2008) Brain Injury 31	(31.3) 68	(68.7) M,	EF,	VF,	A − NA
Oroszi	et	al.	(2006) SLE 46	(78.0) 13	(22.0) M,	A,	EF − NA
Strauss	et	al.	(2004) Depression 43	(69.3) 19	(30.7) M − NA
Zhang	et	al.	(2016) Schizophrenia N	=	1,887 A,	M − N/A
Ho	et	al.	(2007) Schizophrenia 74	(62.2) 45	(37.8) M − N/A
Nagata	et	al.	(2012) Alzheimer 41	(28.1) 105	(71.9) EF + Met/Met	(EF)
Zhang	et	al.	(2012) Schizophrenia 175	(27.0) 474	(73.0) A + Val/Val	(A)
Ho	et	al.	(2006) Schizophrenia 182	(62.1) 111	(37.9) A,	EF,	M + Val/Val	(M)
Lim	et	al.	(2016) Alzheimer 95	(34.7) 179	(65.3) M + Val/Val	(M)
Kim	et	al.	(2016) Schizophrenia 102	(76.7) 31	(23.3) M,	EF,	A + Met	carriers	
(M,	EF,	A)
Narayanan	et	al.	(2016) pTBI 16	(33.3) 32	(66.7) M,	EF,	A + Val/Val	(M,	
EF,	A)
Cao	et	al.	(2016) Depression	(Bipolar) 60	(74.1) 21	(25.9) M + Val/Val	(M)
Altmann	et	al.	(2016) Parkinson 117	(66.8) 58	(33.2) EF + Val/Val	(EF)
Ng	et	al.	(2016) Postchemotherapy 38	(26.2) 107	(73.8) EF,	VF + Met	carriers	
(EF,	VF)
Lee	et	al.	(2015) Alzheimer 16	(15.1) 90	(84.9) EF + Val/Val	(EF)
van	der	Kolk	et	al.	
(2015)
Parkinson 230	(60.0) 154	(40.0) EF,	VF + Met	carriers	
(EF)
Yin	et	al.	(2015) Depression 8	(30.8) 18	(69.2) EF + Met	carriers	
(EF)
Szabo	et	al.	(2013) Cardiovascular 77	(70.0) 33	(30.0) M,	A,	EF,	VF + Met	carriers	
(M,	A,	EF)
Barbey	et	al.	(2014) Brain injury 97	(62.2) 59	(37.8) EF + Met	carriers	
(EF)
Aas	et	al.	(2013) Psychosis 170	(68.3) 79	(31.7) M,	EF,	VF + Val/Val	(M)




McAllister	et	al.	(2012) Brain injury N	=	75 M,	EF + Met	carriers	
(EF)
(Continues)
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in this systematic review. The lack of consistent standards through-
out	could	explain	why	results	were	not	reproducible	across	stud-
ies.	 In	 addition,	 the	 small	 sample	 size	of	 some	 studies,	 especially	




individual	Met/Val	 and	Met/Met	 genotypes	 for	 comparison.	 The	
association reported might also be influenced by ethnicity- a vari-
able that has not been adjusted for. It has been observed that dif-
ferent	 ethnic	 groups	 showed	 differences	 in	 genotypic	 frequency	
of	 the	Val66Met	polymorphism,	with	Caucasians	appearing	more	
susceptible	 to	 effects	 of	 having	Met	 alleles.	 The	 derivative	Met	
allele	 ranges	 from	0%	 in	Africa	 to	 up	 to	60%	 in	Asia,	 and	 a	17%	
frequency	in	Caucasians	(Mandelman	&	Grigorenko,	2012),	entail-
ing that patient groups may need to be matched to make a more 
representative comparison.
Moving	 forward,	 it	 might	 be	 interesting	 to	 note	 how	 BDNF	
polymorphism might have a role in cognitive function especially 
in	 terms	 of	memory.	 If	 there	 is	 indeed	 a	 significant	 association,	
genetic testing could be conducted early on patient groups to seg-
regate	 them	 to	 according	 to	 genotypes	 of	 the	 Val/Val	 homozy-
gotes	or	Met	carriers	for	active	interventions.	If	a	correlation	can	
be found with disease states that are neurological in nature and 
which	collaborate	with	neuroimaging	findings,	it	may	lend	strength	
to the argument for preemptive scanning to be carried out at the 
affected brain regions. Our reviewed studies also suggest that the 
influence of genetics on cognition could become more apparent 
under	certain	disease	states	or	aging.	While	Met	allele	is	hypoth-
esized	 to	 negatively	 affect	 intracellular	 trafficking	 and	 activity-	




study which found that the association between physical activity 
and	 episodic	memory	was	mediated	 by	BDNF	polymorphism,	 as	
Val/Val	homozygotes	were	 found	to	perform	significantly	better	
than	Met	 carriers	 if	 they	were	 active	 in	 physical	 activity,	 show-
ing how that environmental factor can also be a consideration 
(Canivet	et	al.,	2015).
Overall,	 consolidated	 results	 from	 our	 reviewed	 studies	 showed	
that	BDNF	polymorphisms’	relationship	with	cognition	might	be	more	
complex	than	previously	thought.	More	future	studies	could	delve	into	








from the studies focusing on the domain of verbal fluency and atten-
tion/concentration were less conclusive. While more studies might 
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effectVal/Val (%) Met carriers (%)
Rybakowski	et	al.	(2006) Schizophrenia 84	(65.1) 45	(34.9) EF + Val/Val	(EF)
Tan	et	al.	(2005) Schizophrenia 28	(26.0) 80	(74.0) M + Val/Val	(M)
Egan	et	al.	(2003) Schizophrenia 138	(68.0) 65	(32.0) M,	EF + Val/Val	(M)





     |  11 of 14TOH eT al.




ses. Progress in Neuro- Psychopharmacology and Biological Psychiatry,	
46,	181–188.	https://doi.org/10.1016/j.pnpbp.2013.07.008
Acheson,	A.,	Conover,	J.,	Fandl,	J.,	DeChiara,	T.	M.,	Russell,	M.,	Thadani,	
A.,	 …	 Lindsya,	 R.	M.	 (1995).	 A	 BDNF	 autocrine	 loop	 in	 adult	 sen-
sory neurons prevents cell death. Nature,	 375,	 450.	 https:// 
doi.org/10.1038/374450a0
Adachi,	 N.,	 Numakawa,	 T.,	 Richards,	 M.,	 Nakajima,	 S.,	 &	 Kunugi,	 H.	
(2014).	 New	 insight	 in	 expression,	 transport,	 and	 secretion	 of	
brain- derived neurotrophic factor: Implications in brain- related dis-
eases. World Journal of Biological Chemistry,	5(4),	409–428.	https:// 
doi.org/10.4331/wjbc.v5.i4.409
Alfimova,	M.	 V.,	 Korovaitseva,	 G.	 I.,	 Lezheiko,	 T.	 V.,	 &	Golimbet,	 V.	 E.	
(2012).	Effect	of	BDNF	Val66Met	polymorphism	on	normal	variability	
of	executive	function.	Bulletin of Experimental Biology and Medicine,	
152(5),	606–609.	https://doi.org/10.1007/s10517-012-1587-x
Altmann,	 V.,	 Schumacher-Schuh,	 A.	 F.,	 Rieck,	 M.,	 Callegari-Jacques,	
S.	M.,	 Rieder,	 C.	 R.,	 &	 Hutz,	M.	 H.	 (2016).	 Val66Met	 BDNF	 poly-
morphism	 is	 associated	 with	 Parkinson’s	 disease	 cognitive	 impair-




visual memory performance in a healthy cohort. International Journal 





rotrophic factor. PLoS ONE,	9(2),	 e88733.	 https://doi.org/10.1371/
journal.pone.0088733
Bath,	 K.,	 &	 Lee,	 F.	 (2006).	 Variant	 BDNF	 (Val66Met)	 impact	 on	 brain	
structure and function. Cognitive, Affective & Behavioral Neuroscience,	
6(1),	79–85.	https://doi.org/10.3758/CABN.6.1.79
Bekinschtein,	P.,	Cammarota,	M.,	&	Katche,	C.	(2008).	BDNF	is	essential	
to promote persistence of long- term memory storage. Proceedings of 




sual sensory memory processes. Neuropharmacology,	60(2–3),	467–
471.	https://doi.org/10.1016/j.neuropharm.2010.10.028
Bialecka,	 M.,	 Kurzawski,	 M.,	 Roszmann,	 A.,	 Robowski,	 P.,	 Sitek,	 E.	 J.,	
Honczarenko,	 K.,	 …	 Sławek,	 J.	 (2014).	 BDNF	 G196A	 (Val66Met)	
polymorphism	associated	with	 cognitive	 impairment	 in	Parkinson’s	
















performance	 in	 bipolar	 disorder	 patients	 carrying	 the	 BDNF	 val-
66met	 met	 allele.	 Journal of Affective Disorders,	 198,	 198–205.	
https://doi.org/10.1016/j.jad.2016.03.044
Cathomas,	 F.,	 Vogler,	 C.,	 Euler-Sigmund,	 J.	 C.,	 de	 Quervain,	 D.	 J.,	 &	
Papassotiropoulos,	 A.	 (2010).	 Fine-	mapping	 of	 the	 brain-	derived	
neurotrophic	 factor	 (BDNF)	 gene	 supports	 an	 association	 of	 the	
Val66Met	 polymorphism	 with	 episodic	 memory.	 International 








activity and working memory. Frontiers in Human Neuroscience,	10,	
540.
Cherubin,	N.,	Das,	D.,	Tan,	X.,	Bielak,	A.,	Eastel,	S.,	&	Anstey,	K.	J.	(2014).	
Cognitive	 ability,	 intraindividual	 variability	 and	 common	 genetic	
variants of catechol- O- methyltransferase and brain- derived neuro-
trophic	factor:	A	longitudinal	study	in	a	population-	based	sample	of	







polymorphism and hippocampal activation during episodic encoding 
and retrieval tasks. Hippocampus,	21(9),	980–989.
Egan,	M.,	Kojima,	M.,	&	Callicott,	J.	 (2003).	The	BDNF	Val66met	poly-
morphism	affects	activity-	dependent	secretion	of	BDNF	and	human	









posite effects on memory circuits of multiple sclerosis patients and 
controls. PLoS ONE,	 8(4),	 e61063.	 https://doi.org/10.1371/journal.
pone.0061063
Freundlieb,	 N.,	 Backhaus,	 W.,	 Bruggemann,	 N.,	 Gerloff,	 C.,	 Klein,	
C.,	 Pinnschmidt,	 H.	 O.,	 &	 Hummel,	 F.	 C.	 (2015).	 Differential	 ef-
fects	 of	 BDNF	 val(66)met	 in	 repetitive	 associative	 learning	 para-
digms. Neurobiology of Learning and Memory,	 123,	 11–17.	 https:// 
doi.org/10.1016/j.nlm.2015.04.010






(2011).	 The	 Met-	allele	 of	 the	 BDNF	 Val66Met	 polymorphism	 en-
hances task switching in elderly. Neurobiology of Aging,	32(12),	2327.
e7–e19.
Gatt,	 J.	M.,	 Clark,	 C.	 R.,	 Kemp,	A.	H.,	 Liddell,	 B.	 J.,	Dobson-Stone,	 C.,	
Kuan,	S.	A.,	…	Williams,	L.	M.	(2007).	A	genotype–endophenotype–
phenotype path model of depressed mood: Integrating cognitive 




12 of 14  |     TOH eT al.
brain-	derived	neurotrophic	 factor	 (BDNF)	 gene	predicts	decline	 in	
perceptual speed in older adults. Psychology and Aging,	29(2),	384–
392.	https://doi.org/10.1037/a0035201
Gomar,	J.	J.,	Conejero-Goldberg,	C.,	Huey,	E.	D.,	Davies,	P.,	&	Goldberg,	
T.	 E.	 (2016).	 Alzheimer’s	 disease	 neuroimaging	 I.	 Lack	 of	 neural	
compensatory	 mechanisms	 of	 BDNF	 val66met	 met	 carriers	 and	
APOE	E4	 carriers	 in	healthy	 aging,	mild	 cognitive	 impairment,	 and	














cal functioning in a sample of young adults. Neuropsychobiology,	
70(3),	152–157.	https://doi.org/10.1159/000366483
Gosselin,	 N.,	 De	 Beaumont,	 L.,	 Gagnon,	 K.,	 Baril,	 A.	 A.,	Mongrain,	 V.,	
Blais,	H.,	…	Carrier,	J.	 (2016).	BDNF	Val66Met	polymorphism	inter-
acts with sleep consolidation to predict ability to create new declar-
ative memories. Journal of Neuroscience,	36(32),	8390–8398.	https://
doi.org/10.1523/JNEUROSCI.4432-15.2016
Harris,	 S.	 E.,	 Fox,	H.,	Wright,	A.	 F.,	Hayward,	C.,	 Starr,	 J.	M.,	Whalley,	
L.	 J.,	 &	 Deary,	 I.	 J.	 (2006).	 The	 brain-	derived	 neurotrophic	 factor	
Val66Met	 polymorphism	 is	 associated	 with	 age-	related	 change	




polymorphism and the hippocampal volumes in healthy humans: 
A	 joint	meta-	analysis	 of	 the	published	and	new	data.	Neuroscience 
and Biobehavioral Reviews,	 42,	 267–278.	 https://doi.org/10.1016/ 
j.neubiorev.2014.03.011
Ho,	 B.,	 Andreasen,	 N.,	 Dawson,	 J.,	 &	Wassink,	 T.	 (2007).	 Association	
between	 brain-	derived	 neurotrophic	 factor	 Val66met	 gene	 poly-
morphism	 and	 progressive	 brain	 volume	 changes	 in	 schizophre-
nia. American Journal of Psychiatry,	 164(12),	 1890–1899.	 https:// 
doi.org/10.1176/appi.ajp.2007.05111903
Ho,	B.,	Mileve,	P.,	O’Leary,	D.,	Librant,	A.,	Andreasen,	N.,	&	Wassink,	T.	
(2006).	 Cognitive	 and	magnetic	 resonance	 imaging	 brain	 morpho-
metric	 correlates	 of	 brain	 derived	 neurotrophic	 factor	 Val66Met	
polymorphism	in	patients	with	schizophrenia	and	healthy	volunteers.	




gional white matter hyperintensities and cognitive function in elderly 
males without dementia. Psychoneuroendocrinology,	 39,	 94–103.	
https://doi.org/10.1016/j.psyneuen.2013.09.027
Huang,	E.,	&	Reichardt,	L.	(2001).	Neurotrophins:	Roles	in	neuronal	de-
velopment and function. Annual Review of Neuroscience,	24,	677–736.	
https://doi.org/10.1146/annurev.neuro.24.1.677
Jasinska,	K.	K.,	Molfese,	P.	J.,	Kornilov,	S.	A.,	Mencl,	W.	E.,	Frost,	S.	 J.,	
Lee,	 M.,	 …	 Landi,	 N.	 (2016).	 The	 BDNF	 Val66Met	 polymorphism	
influences reading ability and patterns of neural activation in chil-
dren. PLoS ONE,	 11(8),	 e0157449.	 https://doi.org/10.1371/journal.
pone.0157449
Kambeitz,	 J.	 P.,	 Bhattacharyya,	 S.,	 Kambeitz-Ilankovic,	 L.	 M.,	 Valli,	 I.,	
Collier,	 D.	 A.,	 &	 McGuire,	 P.	 (2012).	 Effect	 of	 BDNF	 val(66)met	
polymorphism	 on	 declarative	 memory	 and	 its	 neural	 substrate:	 A	




memory performance in healthy control subjects. Psychiatry Research,	
178(2),	425–429.	https://doi.org/10.1016/j.psychres.2009.09.008
Kennedy,	K.	M.,	Reese,	E.	D.,	Horn,	M.	M.,	Sizemore,	A.	N.,	Unni,	A.	K.,	
Meerbrey,	M.	 E.,	…	 Rodrigue,	 K.	M.	 (2015).	 BDNF	 val66met	 poly-




BDNF	with	hippocampal	volume	and	memory.	Cognitive, Affective & 
Behavioral Neuroscience,	 15(3),	 625–643.	 https://doi.org/10.3758/
s13415-015-0343-x
Kim,	 S.	W.,	 Lee,	 J.	 Y.,	 Kang,	H.	 J.,	 Kim,	 S.	 Y.,	 Bae,	 K.	 Y.,	 Kim,	 J.	M.,	…	
Yoon,	J.	S.	(2016).	Gender-	specific	associations	of	the	brain-	derived	
neurotrophic	 factor	 Val66Met	 polymorphism	 with	 neurocognitive	
and	 clinical	 features	 in	 schizophrenia.	 Clinical Psychopharmacology 





disease. Neurobiology of Aging,	36(3),	1605.e1–e6
Lamb,	Y.	N.,	Thompson,	C.	 S.,	McKay,	N.	S.,	Waldie,	K.	E.,	&	Kirk,	 I.	 J.	
(2015).	 The	 brain-	derived	 neurotrophic	 factor	 (BDNF)	 val66met	
polymorphism differentially affects performance on subscales of 












T.	 L.,	 …	 Dominantly	 Inherited	 Alzheimer	 Network	 (2016).	 BDNF	




BDNF	 Val66Met,	 Aβ	 amyloid,	 and	 cognitive	 decline	 in	 preclini-
cal	 Alzheimer’s	 disease.	Neurobiology of Aging,	34(11),	 2457–2464.	
https://doi.org/10.1016/j.neurobiolaging.2013.05.006
Lin,	P.	H.,	Tsai,	S.	J.,	Huang,	C.	W.,	Mu-En,	L.,	Hsu,	S.	W.,	Lee,	C.,	…	Chang,	





regional gray matter volumes and cognitive function in the Chinese 
population. Neuromolecular Medicine,	 16(1),	 127–136.	 https:// 
doi.org/10.1007/s12017-013-8265-7
Mandelman,	 S.	 D.,	 &	 Grigorenko,	 E.	 L.	 (2012).	 BDNF	 Val66Met	 and	
cognition:	 All,	 none,	 or	 some?	 A	 meta-	analysis	 of	 the	 genetic	 as-




cognition	 and	 symptom	 severity	 in	 a	 brazilian	 population-	based	
     |  13 of 14TOH eT al.
sample of first- episode psychosis subjects. Revista Brasileira de 
Psiquiatria,	34,	219–232.
Matsuo,	K.,	Walss-Bass,	C.,	Nery,	F.	G.,	Nicoletti,	M.	A.,	Hatch,	J.	P.,	Frey,	
B.	N.,	…	 Soares,	 J.	 C.	 (2009).	Neuronal	 correlates	 of	 brain-	derived	
neurotrophic	 factor	 Val66Met	 polymorphism	 and	 morphometric	




derived neurotrophic factor gene influence memory and processing 
speed one month after brain injury. Journal of Neurotrauma,	29(6),	
1111–1118. https://doi.org/10.1089/neu.2011.1930
Mezquida,	G.,	Penades,	R.,	Cabrera,	B.,	Savulich,	G.,	Lobo,	A.,	González-
Pinto,	 A.,	 …	 PEPs	 group.	 (2016).	 Association	 of	 the	 brain-	derived	
neurotrophic	 factor	 Val66Met	 polymorphism	with	 negative	 symp-
toms	 severity,	 but	 not	 cognitive	 function,	 in	 first-	episode	 schizo-
phrenia spectrum disorders. European Psychiatry,	38,	61–69.	https:// 
doi.org/10.1016/j.eurpsy.2016.04.011
Miyajima,	 F.,	 Ollier,	 W.,	 Mayes,	 A.,	 Jackson,	 A.,	 Thacker,	 N.,	 Rabbitt,	
P.,	 …	 Payton,	 A.	 (2008).	 Brain-	derived	 neurotrophic	 fac-
tor	 polymorphism	 Val66Met	 influences	 cognitive	 abilities	 in	
the elderly. Genes, Brain, and Behavior,	 7(4),	 411–417.	 https:// 
doi.org/10.1111/j.1601-183X.2007.00363.x
Molendijk,	 M.	 L.,	 van	 Tol,	 M.	 J.,	 Penninx,	 B.	 W.,	 van	 der	Wee,	 N.	 J.,	
Aleman,	A.,	Veltman,	D.	J.,	…	Elzinga,	B.	M.	(2012).	BDNF	val66met	
affects hippocampal volume and emotion- related hippocampal mem-
ory activity. Translational Psychiatry,	2,	e74.	https://doi.org/10.1038/
tp.2011.72
Montag,	C.,	Felten,	A.,	Markett,	S.,	Fischer,	L.,	Winkel,	K.,	Cooper,	A.,	&	
Reuter,	M.	 (2014).	 The	 role	 of	 the	BDNF	Val66Met	 polymorphism	
in individual differences in long- term memory capacity. Journal of 







Nagata,	 T.,	 Shinagawa,	 S.,	 Nukariya,	 K.,	 Yamada,	 H.,	 &	 Nakayama,	 K.	
(2012).	Association	 between	BDNF	polymorphism	 (Val66Met)	 and	
executive	function	 in	patients	with	amnestic	mild	cognitive	 impair-














Val66Met	 polymorphism	 in	 the	 brain-	derived	 neurotrophic	 factor	
gene confers protection against neurocognitive dysfunction in sys-




BDNF,	 ApoE,	 and	 hypertension.	 Neuropsychology,	 23(1),	 105–116.	
https://doi.org/10.1037/a0013487
Richter-Schmidinger,	 T.,	 Alexopoulos,	 P.,	 Horn,	 M.,	 Maus,	 S.,	 Reichel,	
M.,	 Rhein,	 C.,	 …	 Kornhuber,	 J.	 (2011).	 Influence	 of	 brain-	derived	
neurotrophic- factor and apolipoprotein E genetic variants on hippo-
campal volume and memory performance in healthy young adults. 
Journal of Neural Transmission (Vienna, Austria: 1996),	118(2),	249–257.	
https://doi.org/10.1007/s00702-010-0539-8
da	Rocha,	 F.	 F.,	Malloy-Diniz,	 L.,	 Lage,	N.	V.,	&	Correa,	H.	 (2011).	 The	
relationship	between	the	Met	allele	of	the	BDNF	Val66Met	polymor-
phism and impairments in decision making under ambiguity in pa-
tients with obsessive- compulsive disorder. Genes, Brain, and Behavior,	
10(5),	523–529.	https://doi.org/10.1111/j.1601-183X.2011.00687.x
Rybakowski,	 J.,	 Borkoswka,	 A.,	 Czerski,	 P.,	 Skibinska,	 M.,	 &	 Hauser,	
J.	 (2003).	 Polymorphism	 of	 the	 brain-	derived	 neurotrophic	 fac-
tor gene and performance on a cognitive prefrontal test in bi-
polar patients. Bipolar Disorders,	 5(6),	 468–472.	 https://doi.org/ 
10.1046/j.1399-5618.2003.00071.x
Rybakowski,	 J.,	 Borkoswka,	 A.,	 Skibinska,	 M.,	 Szczepankiewicz,	
A.,	 Kapelski,	 P.,	 &	 Leszcztnska,	 A.	 (2006).	 Prefrontal	 cogni-
tion	 in	 schizophrenia	 and	 bipolar	 illness	 in	 relation	 to	 Val66Met	
polymorphism of the brain- derived neurotrophic factor gene. 
Psychiatry and Clinical Neurosciences,	 60,	 70–76.	 https://doi.org/ 
10.1111/j.1440-1819.2006.01462.x
Schofield,	P.	R.,	Williams,	L.	M.,	Paul,	R.	H.,	Gatt,	J.	M.,	Brown,	K.,	Luty,	
A.,	 …	 Gordon,	 E.	 (2009).	 Disturbances	 in	 selective	 information	
processing	 associated	 with	 the	 BDNF	 Val66Met	 polymorphism:	
Evidence	 from	 cognition,	 the	 P300	 and	 fronto-	hippocampal	 sys-
tems. Biological Psychology,	80(2),	176–188.	https://doi.org/10.1016/ 
j.biopsycho.2008.09.001
Strauss,	K.,	 Barr,	 C.,	&	George,	C.	 (2004).	 BDNF	 and	COMT	polymor-
phisms: Relation to memory phenotypes in young adults with 









diopulmonary fitness and cognition in patients with coronary artery 
disease. Brain, Behavior, and Immunity,	 25(6),	 1264–1271.	 https:// 
doi.org/10.1016/j.bbi.2011.04.017
Szabo,	 A.	 J.,	 Alosco,	 M.	 L.,	 Miller,	 L.	 A.,	 McGeary,	 J.	 E.,	 Poppas,	 A.,	
Cohen,	R.	A.,	&	Gunstad,	J.	(2013).	Brain-	derived	neurotrophic	fac-
tor	Val66Met	polymorphism	and	cognitive	function	in	persons	with	
cardiovascular disease. Psychogeriatrics,	 13(4),	 206–212.	 https:// 
doi.org/10.1111/psyg.12013











phism are not associated with changes in cognitive function follow-
ing a tertiary education intervention in older adults: The Tasmanian 
Healthy	Brain	Project.	Neurobiology of Aging,	55,	 175–176.	https://
doi.org/10.1016/j.neurobiolaging.2017.03.028
Tukel,	R.,	Gurvit,	H.,	Ozata,	B.,	Oztürk,	N.,	Ertekin,	B.	A.,	Ertekin,	E.,	…	
Direskeneli,	 G.	 S.	 (2012).	 Brain-	derived	 neurotrophic	 factor	 gene	
Val66Met	 polymorphism	 and	 cognitive	 function	 in	 obsessive-	
compulsive disorder. American Journal of Medical Genetics. Part B, 
Neuropsychiatric Genetics: The Official Publication of the International 
14 of 14  |     TOH eT al.
Society of Psychiatric Genetics,	 159B(7),	 850–858.	 https://doi.org/ 
10.1002/ajmg.b.32092
Uegaki,	 K.,	 Kumanogoh,	 H.,	 Mizui,	 T.,	 Hirokawa,	 T.,	 Ishikawa,	 Y.,	 &	
Kojima,	M.	(2017).	BDNF	binds	its	pro-	peptide	with	high	affinity	and	
the	 common	 Val66Met	 polymorphism	 attenuates	 the	 interaction.	
International Journal of Molecular Sciences,	18(5),	pii:	E1042.	https://
doi.org/10.3390/ijms18051042
Voineskos,	A.,	 Lerch,	 J.,	 Felsky,	D.,	 Shaikh,	 S.,	 Rajji,	 T.	K.,	Miranda,	D.,	
…	 Kennedy,	 J.	 L.	 (2011).	 The	 brain	 derived	 neurotrophic	 factor	
Val66Met	polymorphism	and	prediction	of	neural	risk	for	Alzheimer	




combine to influence episodic memory function in older adults. 







G.	 (2016).	 The	 BDNF	 Val66Met	 polymorphism	 affects	 encoding	
of object locations during active navigation. European Journal of 
Neuroscience,	45(12),	1501–1511.
Wei,	S.,	Baller,	E.,	Kohn,	P.,	Kippenhan,	J.,	Klolachana,	B.,	Soldin,	S.	J.,	…	
Berman,	 K.	 F.	 (2017).	 Brain-	derived	 neurotrophic	 factor	Val66Met	
genotype and ovarian steroids interactively modulate working 
memory-	related	hippocampal	function	in	women:	A	multimodal	neu-




rebral blood flow and functional connectivity differentially in women 
versus men. Journal of Neuroscience,	 32(20),	 7074–7081.	 https:// 
doi.org/10.1523/JNEUROSCI.5375-11.2012
Wilkosc,	 M.,	 Szalkowska,	 A.,	 Sikibinska,	 M.,	 Zajac-Lamparska,	 L.,	
Maciukiewciz,	M.,	 &	 Araskiewicz,	 A.	 (2016).	 BDNF	 gene	 polymor-
phisms and haplotypes in relation to cognitive performance in Polish 
healthy subjects. Acta Neurobiologiae Experimentalis,	 76,	 43–52.	
https://doi.org/10.21307/ane-2017-004
Yang,	 B.,	 Ren,	 Q.,	 Zhang,	 J.	 C.,	 Chen,	 Q.	 X.,	 &	 Hashimoto,	 K.	 (2017).	
Altered	 expression	 of	 BDNF,	 BDNF	 pro-	peptide	 and	 their	 precur-




polymorphism,	 resting-	state	 hippocampal	 functional	 connectiv-
ity and cognitive deficits in acute late- onset depression. Journal 




morphisms in memory. Molecular Biology Reports,	40(9),	5483–5490.	
https://doi.org/10.1007/s11033-013-2648-6
Yu,	H.,	Zhang,	Z.,	Shi,	Y.,	Bai,	F.,	Xie,	C.,	&	Qian,	Y.	 (2008).	Association	
study	 of	 the	 decreased	 serum	 BDNF	 concentrations	 in	 amnes-
tic	 mild	 cognitive	 impairment	 and	 the	 Val66Met	 polymorphism	 in	




mance	 in	 schizophrenia	 patients	 versus	 healthy	 controls.	 Journal 
of Clinical Psychiatry,	 7(8),	 1011–1018.	 https://doi.org/10.4088/
JCP.15m10269
Zhang,	 X.	 Y.,	 Chen,	 D.	 C.,	 Xiu,	 M.	 H.,	 Haile,	 C.	 N.,	 Luo,	 X.,	 Xu,	 K.,	 …	
Kosten,	 T.	 R.	 (2012).	 Cognitive	 and	 serum	 BDNF	 correlates	 of	
BDNF	Val66Met	gene	polymorphism	in	patients	with	schizophrenia	
and normal controls. Human Genetics,	 131(7),	 1187–1195.	 https:// 
doi.org/10.1007/s00439-012-1150-x
How to cite this article:	Toh	YL,	Ng	T,	Tan	M,	Tan	A,	Chan	A.	
Impact of brain- derived neurotrophic factor genetic 
polymorphism	on	cognition:	A	systematic	review.	Brain Behav. 
2018;8:e01009. https://doi.org/10.1002/brb3.1009
